Results 231 to 240 of about 785,669 (310)

Immune checkpoint inhibitor‐induced arrhythmias: Mechanistic insights from clinical and preclinical studies

open access: yesBritish Journal of Pharmacology, EarlyView.
Immune checkpoint inhibitors (ICIs) have transformed cancer therapy, but their efficacy continues to be limited by immune‐related adverse events. Among these, ICI‐induced cardiac arrhythmias are increasingly recognised as a major adverse reaction, encompassing a broad spectrum of clinical phenotypes, including conduction blocks, atrial fibrillation and
Anand R. Ramalingam   +3 more
wiley   +1 more source

Therapeutic access points: The roles of circumventricular organs in drug delivery and metabolic regulation

open access: yesBritish Journal of Pharmacology, EarlyView.
The current obesity drug landscape, dominated by GLP‐1 receptor agonists and emerging multi‐agonist therapies, has reinforced that long‐term weight loss is achieved in large part through central mechanisms that suppress appetite and reshape energy balance.
Ines Martinez‐Corral   +3 more
wiley   +1 more source

Differing roles of the calcitonin gene‐related peptide (CGRP) and amylin receptors in migraine‐related light aversion and gastrointestinal dysfunction in mice

open access: yesBritish Journal of Pharmacology, EarlyView.
Background and Purpose The neuropeptide calcitonin gene‐related peptide (CGRP) is a well‐established player in migraine. Current CGRP migraine therapeutics were designed to inhibit the canonical CGRP receptor, yet, based on in vitro studies, they can also inhibit to a lesser degree the amylin receptor 1 (AMY1), which CGRP can also activate.
Jayme S. Waite   +10 more
wiley   +1 more source

Expanding the Utility of Gold Nanocluster “Allergolds” to Peanut Allergen Ara h 2

open access: yes
Allergy, EarlyView.
Gage O. Leighton   +10 more
wiley   +1 more source

Artificial intelligence-assisted design of MAGE-A4 ×CD16 T-cell receptor-like natural killer cell engagers. [PDF]

open access: yesMAbs
Liu Y   +10 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy